Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis

Introduction and aim. Approximately 650,000 people in Brazil have chronic hepatitis C virus (HCV) infection. We evaluated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus dasabuvir (DSV) with/without ribavirin (RBV) in an open-label multicenter phase 3b trial in trea...

Full description

Bibliographic Details
Main Authors:	Mario G. Pessoa, José V. Ramalho-Madruga, Katia Alves, Estevão P. Nunes, Hugo Cheinquer, Carlos E. Brandão-Mello, Maria C. Mendes-Correa, Maria L. Ferraz, Paulo R.A. Ferreira, Mário R. Álvares-da-Silva, Henrique S. Coelho, Evaldo S. Affonso-de-Araújo, Juvencio Furtado, Raymundo Parana, Giovanni Silva, Sara A. Lari, Li Liu, Rakesh Tripathi, Tami Pilot-Matias, Daniel E. Cohen, Nancy S. Shulman, Ana Martinelli
Format:	Article
Language:	English
Published:	Elsevier 2018-11-01
Series:	Annals of Hepatology
Subjects:	Chronic hepatits C Direct-acting antivirals Genotype 1 Advanced fibrosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268119310580

Similar Items

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
by: David E. Bernstein, et al.
Published: (2019-02-01)

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4
by: Daniel H. Leung, et al.
Published: (2018-11-01)

Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial
by: Liat Deutsch, et al.
Published: (2020-04-01)

Severe hepatotoxicity of ritonavir, ombitasvir, paritaprevir, and dasabuvir in a kidney transplant recipient
by: Nikolina Bukal, et al.
Published: (2019-01-01)

On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series
by: Madelyne Bean, et al.
Published: (2016-01-01)

Drug Interaction with Cyclosporine and Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Regimen for HCV in Organ Transplant Recipients
by: Yu-Hsuan Huang, et al.
Published: (2018)

Efficacy and Safety of the Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Regimen for Chronic Hepatitis C in Hemodialysis Patients
by: Güven Gürkan TOSUN, et al.
Published: (2019-12-01)

Suicidal ideation in patients treated with ombitasvir/paritaprevir/ritonavir (Viekirax®), dasabuvir (Exviera®) and ribavirina (Rebetol®)
by: Jose Carlos de Miguel Bouzas, et al.
Published: (2016-09-01)

Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
by: Jingjing Wu, et al.
Published: (2019-01-01)

Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in treatment of patients with chronic hepatitis C in the Republic of Srpska: A real-life study
by: Verhaz Antonija, et al.
Published: (2019-01-01)

Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report
by: Rahul Kumar, et al.
Published: (2019-09-01)

Real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir +ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia
by: Simonović-Babić Jasmina, et al.
Published: (2019-01-01)

Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection
by: Smith MA, et al.
Published: (2015-11-01)

A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection
by: Hsuan-Yu Hung, et al.
Published: (2021-09-01)

Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience
by: Ming-Lung Yu, et al.
Published: (2018-06-01)

Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.
by: Maya Leventer-Roberts, et al.
Published: (2017-01-01)

Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
by: Hussaini T
Published: (2016-05-01)

Efficacy and Safety of Ombitasvir, Paritaprevir and Ritonavir plus Ribavirin in Hepatitis C Genotype-4 Patients on Hemodialysis
by: Mai Abdelmen, et al.
Published: (2020-09-01)

A study of Artificial Intelligence for Prediction on the Risk of Liver Decompensation Induced by Paritaprevir/ Ritonavir/ Ombitasvir Plus Dasabuvir (ProD) Antiviral
by: Liang-Yu Hsia, et al.
Published: (2019)

Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
by: Yi-Chung Hsieh, et al.
Published: (2018-01-01)

Clinical effect of 3D regimen (paritaprevir/ritonavir/ombitasvir combined with dasabuvir) in treatment-naive patients with genotype 1b chronic hepatitis C
by: WANG Bowen, et al.
Published: (2017-06-01)

Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
by: José Manuel Sousa, et al.
Published: (2019-01-01)

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients.
by: Lucia Taramasso, et al.
Published: (2018-01-01)

Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction
by: Shih Yea Sylvia Wu, et al.
Published: (2017-01-01)

Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
by: Naglaa El-Gendy, et al.
Published: (2020-01-01)

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study
by: Ewa Janczewska, et al.
Published: (2018-11-01)

The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis
by: Muhammad M A. Ghaffar, et al.
Published: (2021-01-01)

Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients
by: Haruki Uojima, et al.
Published: (2019-01-01)

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
by: Bernstein D, et al.
Published: (2019-02-01)

Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 weeks in chronic HCV hepatitis genotype 1b
by: Mircea Manuc, et al.
Published: (2021-03-01)

Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort
by: Jan Sperl, et al.
Published: (2018-04-01)

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease
by: Eric Lawitz, et al.
Published: (2019-02-01)

Effectiveness and safety of ombitasvir/paritaprevir/ritonavir in treatment of chronic hepatitis C Egyptian hemodialysis patients, case-control study
by: Nahla Mohamed Teama, et al.
Published: (2021-01-01)

Development and validation of eco-friendly micellar-HPLC and HPTLC-densitometry methods for the simultaneous determination of paritaprevir, ritonavir and ombitasvir in pharmaceutical dosage forms
by: Adel Ehab Ibrahim, et al.
Published: (2019-04-01)

A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir
by: Kazuo Tarao, et al.
Published: (2017-06-01)

Clinico-laboratory and immunological characteristics of patients with compensated cirrhosis of the liver in the outcome of chronic hepatitis C on the background of treatment with a direct antiviral drug paritrapeprir/ritonavir/ombitasvir/ dasabuvir
by: L. L. Popova, et al.
Published: (2018-12-01)

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
by: Yan-Ming Zeng, et al.
Published: (2020-05-01)

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial
by: Mario G. Pessôa, et al.
Published: (2012-01-01)

Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach
by: Dario Akaberi, et al.
Published: (2018-01-01)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
by: Yin-Qiu Huang, et al.
Published: (2020-07-01)